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Abstract
Long term non-progressor patients (LTNPs) are characterized by the natural control of HIV-1 infection. This control is related
to host genetic, immunological and virological factors. In this work, phylogenetic analysis of the proviral nucleotide
sequences in env gene from a Spanish HIV-1 LTNPs cohort identified a cluster of 6 HIV-1 controllers infected with closely-
related viruses. The patients of the cluster showed common clinical and epidemiological features: drug user practices,
infection in the same city (Madrid, Spain) and at the same time (late 70’s-early 80’s). All cluster patients displayed distinct
host alleles associated with HIV control. Analysis of the virus envelope nucleotide sequences showed ancestral
characteristic, lack of evolution and presence of rare amino-acids. Biological characterization of recombinant viruses with
the envelope proteins from the cluster viruses showed very low replicative capacity in TZMbl and U87-CD4/CCR5 cells. The
lack of clinical progression in the viral cluster patients with distinct combinations of protective host genotypes, but infected
by low replicating viruses, indicate the important role of the virus in the non-progressor phenotype in these patients.
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Introduction
Long term non-progressor patients (LTNPs) are individuals
infected with HIV-1 for more than 10 years, maintaining high
CD4+ lymphocytes numbers without clinical symptoms in absence
of therapy [1]. Within the LTNPs group and according to HIV-1
plasma viral load, we can distinguish LTNP non controllers
(LTNP-NC) with viral loads above 2000 copies/ml, LTNP viremic
controllers (LTNP-VC) with viral load between 50–2000 copies/
ml and LTNP elite controllers (LTNP-EC) with undetectable viral
loads (,50 copies/ml) [2].
Host genetic, immunological and virologic factors have been
investigated in relation to the natural control in HIV-1 LTNPs.
Control of viral replication was associated with the presence of
certain human leukocyte antigen (HLA) class I alleles, particularly
in the HLA-B locus like the HLA-B57/B27 haplotypes with a
significantly higher frequency in HIV-1 controller cohorts [3,4].
Results of genome-wide association studies (GWAS) confirmed
only two groups of genetic polymorphisms in the HLA-B and C
locus involved in viral replication control [5–8]. Qualitative
attributes of innate and adaptive immune response was associated
with viral control of HIV-1 infection [9,10]. In this control, the
importance of antigen sensitivity and T-cell receptor avidity were
reported [11].
Different studies described the correlation between in vitro HIV
replication and the level of plasma virus load and disease
progression in chronic progressors [12] but also in non-progressors
patients [13–15]. Several studies reported defective virus in LTNP
patients [16–18] but other works defined the presence of
replication competent viruses in HIV-1 LTNP controller patients
[19,20]. Rigorous fitness studies on isolated HIV-1 gene products
from HIV-1 controllers indicated that gag, pol and env genes
contribute to a reduced replicative fitness [21–23]. Except from
the Sydney Blood Bank Cohort [24] which included LTNPs
patients infected with an attenuated nef/LTR HIV-1 strain, no
evidence of a cluster of viruses among HIV-1 LTNP controllers
has been described [19,20].
In this study, we identified by phylogenetic methods, a viral
cluster in the sequences from a cohort of Spanish LTNPs. The
patients of the cluster shared epidemiological and clinical data
supporting the phylogenetic clustering, and they showed host HLA
II alleles associated with viral control. In addition, as a first
characterization, we analyzed the replicative capacity of recombi-
nant viruses with env gene form the cluster patient’s viruses, and
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identified, in comparison with subtype B sequences, rare amino
acids specific of the cluster viruses.
Materials and Methods
Ethic Statement
Participants gave informed consent for genetic analysis studies,
which was oral and general for different type of studies for
participants with a long term follow-up. Written consent was not
obtained from a collection of samples drawn in 1989 from patients
without clinical follow-up (included as control Spanish samples in
Figure 1 and Fig. S1) because this requirement was not necessary
at this time. The remaining samples correspond to patients in
follow-up, in which first samples were with oral consent but the
written consent was obtained later during the follow-up. The
consents were approved by the Ethical and Investigation
Committees of the different centers: Centro Sanitario Sandoval
(Madrid), Fundació IrsiCaixa (Badalona), Hospital 12 de Octubre
(Madrid) and collaborator centers of the HIV BioBank integrated
in the Spanish AIDS Research Network (RIS). All clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki. The investigation was
approved by the Comité de Ética de la Investigación y de
Bienestar Animal of the Insituto de Salud Carlos III with CEI PI
05_2010-v3 number.
Study Population
Set 1 was formed by 56 HIV-1 complete env nucleotide
sequences from 55 Spanish patients. This set included 41 LTNPs
patients, mostly infected in the 80’s, kindly provided by the Centro
de Salud Sandoval, the Fundació IrsiCaixa, the Hospital 12 de
Octubre and the HIV BioBank integrated in the Spanish AIDS
Research Network (RIS). In addition, we included 3 LTNPs
Spanish patients whose nucleotide sequences were deposited in the
Los Alamos National Laboratory HIV Database (LANL database,
http://www.hiv.lanl.gov) [25]. The remaining 11 samples were
collected in 1989 from HIV-1 patients without clinical follow-up.
Table S1 summarizes the available clinical and virological
characteristics of these individuals.
Reference Nucleotide Sequences
Set 2 was formed by a group of 128 complete env nucleotide
sequences from non-Spanish HIV-1 patients selected in LANL
database. It included sequences obtained at the beginning of the
subtype B HIV-1 epidemic (68 from North-America prior to 1991
and 32 from Europa prior to 1996), 25 sequences from HIV-1
controllers previously described [19,20] and three subtype D
sequences used as outgroup (sample identification and Gene Bank
accession number are found in Table S2).
Env Gene Amplification, Nucleotide Sequencing and
Phylogenetic Analysis
Complete env nucleotide sequences from 39 patients included in
the set 1 were obtained from proviral DNA by single genome
amplification (SGA) as described [17]. The remaining 16
nucleotide sequences from set 1 were kindly provided by Dr.
Delgado (Hospital 12 de Octubre) or obtained from the LANL
database. Nucleotide sequences of the non-Spanish group (set 2)
were also included in this phylogenetic analysis.
In total, 184 sequences were aligned with CLUSTAL X 2.0
program [26], and Gblocks program [27] was used to eliminate
poorly aligned positions, primarily in the variable regions.
Phylogenies were estimated using a classical and a Bayesian
approach, both functioning under a maximum likelihood (ML)
criterion and without assuming any molecular clock. The
classical approach was implemented using the best-fit model
of nucleotide substitution (GTR+G+I, jModelTest v.0.1.1) [28]
in PhyML 3.0 program [29] in order to calculate the ML tree.
Internal branches support was tested with an approximate
likelihood-ratio test [30].
The Bayesian approach was implemented by using MrBayes
v.3.2 [31] with the GTR+G+I model of nucleotide substitution.
Four independent MCMCMC (Metropolis-Coupled Markov
Chain Monte Carlo) runs starting from a random tree were
calculated, each for 36107 generations, with a burn in of 66106
generations from each run. Examination of MCMCMC samples
with Tracer 1.3 [32], indicated the adequate mixing of the
MCMCMC. Phylogenetic trees were visualized using FigTree
v.1.3 (http://tree.bio.ed.ac.uk).
Most recent common ancestor (MRCA)-to-tip distances were
extracted from MrBayes phylogenetic tree using TreeStat v.1.2
(http://www.tree.bio.ed.ac.uk/software/treestat). Because no mo-
lecular clock was assumed for the analysis, we tested the
correlation between genetic distances to the MRCA and sampling
time of nucleotide sequences obtained at the beginning of the
HIV-1 epidemic (years 1981–1995). This correlation was used to
estimate the ‘‘viral dating’’ of the nucleotide sequences from the
cluster viruses.
Complete env Gene Sequences Analysis
The amino acid sequences of HIV-1 cluster were compared to
consensus B sequence obtained from LANL database. Each amino
acid position modified in at least 5 sequences from the cluster
viruses was compared to the ancient (110 nucleotide sequences
prior to 1996 from set 1 and 2) and Spanish (50 sequences from set
1) groups in our alignment and with the complete env subtype B
amino acid sequences included in the 2006 web alignment of the
LANL database (452 sequences). For the comparison of the cluster
sequences with each set of sequences, a statistical analysis was
performed with the non-parametric Mann-Whitney U test with a
restrictive significance at the 99.9%.
We also compared the gp160 total length and the length
variation in the gp120 loops (number of amino acid between
cysteine residues), V1/V2 (amino acid 130 to 190 in subtype B
consensus), V3 (amino acid 293 to 327), V4 (amino acid 380 to
405), V5 (amino acid 447 to 456) and in the gp120 signal peptide
(SP) (amino acid 1 to 34). Potential N-linked glycosylation sites
(PNLGS) were also predicted using the N-GLYCOSITE web tool
(http://www.hiv.lanl.gov content/sequence/GLYCOSITE/glycosite.html).
Virus Isolation from Patient’s Peripheral Blood
Mononuclear Cells (PBMC)
PBMC and plasma samples were obtained from the patients as
described [33]. Virus isolation from purified CD4+ T cells was
attempted by co-culture as previously described [17]. Co-cultures
were maintained for one month and tested for p24 production by
the electrochemiluminescence Immunoassay ECLIA using Elecsys
2010 immunoassay analyzers (Roche Diagnostic).
Generation of Recombinant Viruses
Full-length env genes from three patients of the cluster (LTNP_1,
LTNP_3 and LTNP_RF_21), from three HIV-1 infected chronic
progressors (I10 and IV10 obtained in 1993 from IDU patients
and RIS06) and one laboratory adapted virus (SF-162) were
cloned into 89ES061 molecular clone, derived from a Spanish
field isolate [34]. Molecular clone 89ES061 was SapI digested, gel
extracted using PureLink Quick Gel Extraction Kit (following the
Viral Cluster in HIV-1 Controllers
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e77663
Figure 1. Phylogenetic tree from the Bayesian MCMC (MrBayes) analysis. The 50% majority rule consensus was constructed and posterior
probabilities are indicated by asterisks in nodes (black * upper 0.85 and red * upper 0.95). MRCA including the vast of majority sequences analyzed
(black ¤) and MRCA from the cluster viruses (red ¤) are marked. Branch lengths represent the mean value observed for that branch among the
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manufacturer instructions, Invitrogen) and ligated with the gp160
amplicons using T4 DNA ligase (New England Biolabs).
Recombinants plasmids were transformed in DH5a competent
cells and clones sequenced to check the correct insert orientation.
In order to generate the recombinant viruses, 20 mg of the
recombinant plasmids were transfected into 36106 293T cells
using a calcium chloride protocol [35]. 293T cells were
maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin and 100 mg de streptomycin/ml (DMEMc).
72 h post-transfection, supernatants were harvested and filtered
through 0.45 mm to remove cellular debris. Virus production
was quantified measuring in the supernatants HIV-1 p24
antigen by electrochemiluminescence Immunoassay (Roche
Diagnostic) and reverse transcriptase (RT) activity using a
Syber green I-based real-time PCR enhanced RT assay
(SGPERT) [36].
Viral Titer Determination
Recombinant virus titration was performed in 104 TZM-bl cells
with 100 mL of serial 10-fold dilutions of viral stocks; each dilution
was assayed six times. After 48 h, cells were stained for b-
galactosidase activity as described [37]. Titers represented the
mean and standard error of three independent assays and they
were expressed in tissue culture infective dose per ml (TCID/ml),
calculated by the Spearman–Karber formula [38].
Replicative Capacity of Cluster Viruses
Viral infectivity of recombinant viruses was assayed in
duplicate by infection of 105 TZM-bl cells with fifteen p24
antigen units of recombinant viral stocks, corresponding to
75 pg, in the presence of 40 mg/mL of DEAE-dextran. After 48
hours of incubation, infection levels were determined by
luciferase activity of cell lysates using the luciferase assay system
(Promega). As negative control luciferase activity from a
transfection supernatant without plasmid was used. Luciferase
activity values were normalized to the luciferase activity of wild-
type (WT) virus (89ES061 clone).
Replicative capacity of recombinant viruses was also assayed by
infection of U87-CD4/CCR5 cells. U87-CD4/CCR5 cells were
cultured in DMEM supplemented media with 15% fetal bovine
serum plus 300 mg/ml G418 (Sigma-Aldrich) and 1 mg/ml
puromycin (Sigma-Aldrich). 56104 U87-CD4/CCR5 cells per
well were seeded in a 24 well plate and infected with 100 units
(corresponding approximately to 500 pg) of p24 antigen of the
different viruses. Virus production was quantified by measuring
the RT-activity in the supernatants. Cultures were sub-cultured
during 14 days.
Characterization of Genetic Markers of the Patients
The host genetic polymorphisms studied were chosen on the
basis of GWA studies or selected from the literature [2]. These
included the HCP5 rs2395029 allele in linkage disequilibrium with
HLA-B*5701, the HLA-C-35 (rs9264942) variant, CCR5 D32
(rs333), CCR2 V64I (rs1799864), ZNRD1 (rs3869068) and HLA-
class I (A, B, C).
Nucleotide Sequence Accession Numbers
The new sequences reported in this paper have been deposited
in the GeneBank database (accession numbers: KC595149-
KC595178, KC595182-KC595203 and KC595221).
Results
Identification of a Viral Cluster in a Spanish HIV-1 LTNPs
Cohort
The global and quasispecies nucleotide sequences from a
cohort of Spanish LTNPs and chronic patients, obtained
between 1989 and 2005, were analyzed by Maximum Like-
lihood (ML) in the gp120 C2-V5 region in env gene (Figure S1).
This analysis showed that all nucleotide sequences obtained in
different time points from each patient formed monophyletic
clades, except sequences from 6 individuals. These sequences
could not be segregated per patient, and they formed a
phylogenetic cluster with short branch lengths and very low
mean genetic distances among sequences (1.1%) although
samples were recovered during 16 years (1989–2005). Viral
dating of the nucleotide sequences from the cluster viruses,
according to the methodology described for Spanish viruses [39]
indicated the ancestral characteristics of the virus (Table 1), i.e.
viral dating close to the time of primoinfection [39]. All patients
included in the cluster had intravenous drug practices (IDU) in
the late 70’s and early 80’s; they lived in Madrid and had a first
HIV-1 positive serology between1985 and 1990 (Table 1).
Clinical and virological follow-up, for over 15 years, was only
possible in five of the six patients. Four of them were LTNP-EC
(LTNP_3, LTNP_5, LTNP_RF_21 and LTNP_RF_15) and one
was a LTNP-VC (LTNP_1) (Table 1 and Figure S2) [2].
Except for LTNP_RF_21 (Table 2), all patients showed an
HLA-B haplotype associated with viral control (B27**, B57**/
B58** and B51**) and all individuals presented an accumulation of
genetic polymorphisms HLA-C-35 (rs9264942), CCR5 D32 (rs333)
and CCR2 V64I (rs1799864) associated with lack of clinical
progression (Table 2). In summary, we detected in a cohort of
Spanish HIV-1 LTNP patients, a cluster of epidemiologically
linked individuals, with genetic factors associated with the control
of HIV-1 replication, and infected with closely-related ancestral
viruses.
Phylogenetic Confirmation of the Viral Cluster
For the clarification of the phylogenetic history of the cluster
viruses and the exclusion that clustering was due to the ancestral
characteristic of the viral nucleotide sequences, we extended the
phylogenetic study to the complete env gene and to nucleotide
sequences from the beginning of the HIV-1 epidemic. For this
analysis, we used only one sequence from set 1 and set 2 of
nucleotide sequences (Materials and Methods and Table S1 and
S2). As only 11 Spanish nucleotide sequences prior to 1996 could
be obtained, we analysed nucleotide sequences from Spanish
LTNPs, obtained between 1998 and 2005, but infected in the 80 s
and early 90 s (see Table 1). The phylogenetic trees obtained by
ML (data not shown) and Bayesian approach (Figure 1) identified
the same viral cluster than in the C2-V5 fragment (Figure S1). The
posterior probability for the viral cluster was 0.87 and it increased
to 0.98 when patient LTNP_RF_15 was not considered.
post-burning sampled trees. The branch colors identified nucleotide sequences origin: black correspond to ancient sequences from North-America
(before 1991) and from Europe (before 1995), blue are Spanish sequences (from 1989 and 2005) and red Spanish cluster sequences (from 2004–2005,
except As7 which was from 1989). Green sequences are from elite suppressors [54] and yellow sequences from elite controller patients [54]. Gray lines
are D subtype sequences used as outgroup in the bottom of the tree.
doi:10.1371/journal.pone.0077663.g001
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Another striking characteristic of the viral cluster was the very
low genetic distance to the most recent common ancestor
(MRCA), marked in Figure 1, which includes the majority of the
samples analyzed. Except for three samples, the mean genetic
distance of the cluster to the MRCA was among the shortest in the
tree with a value of 4.85%. This value demonstrated the proximity
of the viral cluster to the origin of the subtype B epidemic in the
developed countries.
The Bayesian inference was done with no molecular clock
assumption and then it was possible to test the correlation
between the genetic distance to the MRCA and the sampling
year for the HIV-1 sequences collected at the beginning of
subtype B epidemic in developed countries (years 1981–1995)
(Figure 2). In spite of scattered data, a good correlation was
obtained between genetic distance and sampling time (r2 = 0.57,
p-value ,0.0001) and with a divergence rate of 0.81%/year.
Although samples from the cluster patients were collected
between 2004 and 2005, the extrapolation of the genetic
distance to the MRCA allowed the viral dating of the cluster
samples at around 1977–1978, thus confirming the ancestral
characteristics. The low genetic distance to the MRCA and the
ancestral viral dating, implying 27–28 years of infection,
confirmed the lack of viral evolution in these patients.
Table 1. Epidemiological, clinical and virological characteristics of the cluster patients.
Patient
Birth














LTNP 1 1954 F Madrid C.S.Sandoval IDU 1978–80 1990 Ancestral 285 745 1333 1a/1b
LTNP 3 1956 M Madrid C.S.Sandoval IDU 1976–82 1988 Ancestral ,50 775 570 1b
LTNP 5 1962 M Madrid C.S.Sandoval IDU 1980–88 1986 Ancestral 210 876 1302 1a
89 AS7 1965 F NK El Patriarca IDU NK 1989 Ancestral NK NK NK NK
LTNP RF 15 1964 M Madrid 12 de Octubre IDU 1985–94 1989 Ancestral ,50 478 810 3


















LTNP_1 11 11 11 12 11 0201 2401 1501 2705 2
LTNP_3 11 11 11 22 11 0201 0205 2705 5801 4
LTNP_5 12 12 11 22 11 0201 6801 2705 3503 4
AS7 12 11 11 12 11 0301 6901 3501 5101 3
LTNP RF 15 11 11 ND 11 ND 02 24 44 57 1
LTNP RF 21 12 11 ND 22 ND ND ND 47 14 3
For SNPs, 1 indicates the most common and 2 the variant allele. Protective HLA alleles included B*2705, B*5701, B*5101, B*1302, A10 serogroup (A*2501, A*2601) and
A*3201. Risk HLA alleles included B*35Px (B*3503), B22 serogroup (B*55, B*56), B*1801, A*2402 and A*2301.
aAdditive unweighted genetic scores were used to compile genetic information: CCR2 V64I [0,1,2], CCR5 D32 [score 0,1], HLA-C–35 [0,1,2], and protective HLA-B+ [0,1,2]
and detrimental HLA-B- alleles [0,21,22]) according to [1]: 0: regular font, +1: bold, +2: bold and italic and 21 italic.
doi:10.1371/journal.pone.0077663.t002
Figure 2. Correlation between sampling time and the genetic
distance with reference and viral cluster strains. MRCA-to-tip
distances were extracted from MrBayes phylogenetic tree using
TreeStat v.1.2. N, values obtained for the nucleotide sequences
collected at the beginning of HIV-1 epidemic (years 1981–1995) were
plotted against sampling time and a linear regression analysis was
performed. Red D, values obtained from the cluster nucleotide
sequences. The red dashed line and the arrow permit the extrapolation
of the year from cluster nucleotide sequences.
doi:10.1371/journal.pone.0077663.g002
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Env Gene Length and Potential N-linked Glycosylation
Sites in the Viruses of the Cluster
The total env gene length, the V1 to V5 loop and signal peptide
(SP) lengths and the number of potential N-linked glycosylation
sites (PNLGS) in the cluster sequences were compared to three
sequence groups: the 2006 reference alignment from the LANL
database (454 subtype B sequences), the 110 ancient sequences
group (obtained prior to 1996 from set 1 and set 2) and the 50
Spanish sequences group (set 1) from our alignment. The gp160
protein total length (849 amino acids) and the number of PNLGS
(26–28 sites) from the cluster nucleotide sequences were very
similar in all patients confirming infection with closely-related
viruses. These values were significantly lower (p,0.0005) than
those in the three control sets (Figure 3A). Analysis of the gp120
loops and the SP lengths revealed that the differences in total
length were attributed to significant differences in the V1–V2 and
V4 regions (Figure 3B). The identical positions of the PNLGS
support the relatedness of the viruses, and the short length of the
variable loops the ancestral dating of the cluster viruses.
Biological Characterization of Viruses from the Cluster
For the identification of viral factors potentially implicated in
the lack of evolution detected in these patients, virus isolation was
attempted from purified CD4+ T cells at least twice in three cluster
patients (LTNP_1, LTNP_3 and LTNP_5). All co-cultures were
negative, except for one LTNP_1 sample. In this case, although
co-culture supernatant was antigen p24 positive, we were unable
to propagate the virus in donor peripheral blood mononuclear
cells (PBMCs).
Since we could not isolate the viruses, as a first characteriza-
tion of the biology of the viruses, we analyzed recombinant
viruses with the env gene from proviral DNA of patients
LTNP_1, LTNP_3 and LTNP_RF_21. This cloning was carried
out into the laboratory infectious clone 89ES061 from a natural
Spanish isolate (see Materials and Methods). We also obtained
recombinant viruses from three control HIV-1 infected chronic
progressor patients (I10, IV10 and RIS06) and one laboratory
adapted CCR5-virus (SF-162) and they were assayed in different
cell lines.
To perform the biological characterization of the recombinant
viruses obtained by transfection in 293T cells, p24 antigen, RT-
activity and TCID50 were determined in the transfection super-
natant and the results are shown in Table 3. We found a direct
correlation between the p24 level and the RT-activity (R2 = 0.96,
p,0.0001 Pearson correlation) but not with the infectious titer.
Although lower values were observed in p24 antigen levels and
RT- activity, no large differences between the cluster viruses and
the other viruses, except from virus from patient LTNP_RF_21,
were detected. All recombinant viruses from the cluster showed
low infectivity titers, with a maximum of 6.26102 TCID50, which
are 10 to 100 times lower than control viruses. The titer/p24
antigen ratio from cluster recombinant viruses was between 0.22
and 2.73; ratio from chronic viruses ranged between 10.89 and
21.29, while the ratio of the WT and the SF-162 reference viruses
was 17.13 and 94.16 respectively. Then, the cluster viruses showed
titer/p24 antigen ratios that were from 6–78 folds lower than those
of WT virus and 34–428 lower than SF-2 virus.
Infectivity of the cluster and chronic recombinant env clones was
also tested by measuring luciferase activity in TZM-bl cells. For
these experiments, TZM-bl cells were infected with a fixed amount
of antigen p24 from the transfection supernatants (see Materials
and Methods). Again, the luciferase activity from all recombinant
viruses from the cluster patients was significantly decreased, with
values ranging from 0 to 40% those of the WT virus (Figure 4A).
Finally, the recombinant viruses were used for infection of U87-
CD4/CCR5 cells. In this experiment, cells were infected with 100
units of p24 antigen (500 pg) of recombinant viruses. Cultures
were followed during 14 days, and HIV-1 production quantified
measuring RT-activity in the supernatant. In this case, as the WT
virus could not be used as control because it is a CXCR4 virus, we
employed the laboratory adapted SF-162 virus. The replication
curves are shown in Figure 4B. The replication kinetics of the
cluster viruses were clearly retarded relative to chronic patient or
control viruses. Only two (LTNP_1_10 and LTNP_3_22) of the
six clones from the cluster patients reached detectable but low
replication levels (with a maximum of 5.06102 arbitrary units,
AU) which are at least 10 times lower than the control values. In
addition, two other cluster viruses (LTNP_1_12 and LTNP _3_3)
showed extremely low levels (15 and 28 AU respectively) of viral
replication only 14 days post-infection. Finally, the other two
cluster viruses did not replicate (LTNP_3_20 and LTNP_RF_21).
All these results indicated that the cluster viruses were low and
slow replicating viruses.
Env Amino-acid Analysis in the Cluster Viruses
Once the existence of the cluster viruses and the low replicative
capacity of the recombinant viruses with the envelopes from the
patients were confirmed, we investigated the amino acid that could
be associated with this phenotype. For this reason, we compared
the env amino acid sequences of the cluster viruses with the subtype
B consensus sequence obtained from the LANL database
(Figure 5). Mutations, insertions and/or deletions in the envelope
variable regions V1 to V5 were not included in this analysis. We
detected the presence of 35 mutated positions common to at least
5 of the 6 viruses. We determined how often these 35 positions
were altered in the three sample groups described in env length and
PNLGS paragraph (2006 LANL database reference alignment, the
ancient sequences group and the Spanish sequences group). This
analysis permitted the removal of positions in the cluster viruses
that could represent ancestral characters or a founder effect in the
Spanish HIV-1 epidemic. The presence or absence of every cluster
virus mutation into each set of sequences was compared using the
non-parametric Mann-Whitney U test. This analysis reduced the
number of potential characteristic mutations from 35 mutations to
11, which are highlighted in Table 4. In previous studies, the
identification of signature amino acids in viruses from HIV
controller patients was associated with loss of replicative capacity
and fitness [13,20,23,40].
Nine of these mutations were located in the gp120. Six of them
(I319T, N335D, K343R, F349L, N381D and G392V) mapped to
the V3-C4 region, two mutations (K4E and M25I) correspond to
the SP and one to the V1 region (L133W). The two gp41
mutations were E110K, next to the gp41 immunodominant C-C
loop, and G226D in the Kennedy epitope in the cytoplasmic tail.
The statistical analysis performed in the viral cluster, identified 11
unusual amino acids that could be related to the lack of viral and
clinical evolution in the patients.
Presence of the Cluster Specific Residues in Functional
Viruses
The role of the residues, identified by the statistical analysis,
in the replicative characteristics of the viruses was confirmed in
comparison with functional viruses derived from the cluster
patients. To this end, we used viral nucleotide sequences from
the viremic patient LTNP 1. LTNP 1 was the only patient in
which we obtained a positive co-culture in one of the samples.
The virus from the supernatant of this co-culture was partially
sequenced in the C2-V5 region in env gene. In addition, this
Viral Cluster in HIV-1 Controllers
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Figure 3. Envelope analysis of the cluster viruses. A) Envelope length in amino acids and N-linked glycosylation sites (NxT/S). B) V1 to V5 loop
and signal peptide (SP) lengths in the amino acid sequence sets analysed. Red cluster nucleotide sequences, blue Spanish nucleotide sequences,
Viral Cluster in HIV-1 Controllers
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patient after 20 years of infection showed an increase in the
plasma viral load (Figure S2). A sample from this blip was
obtained and the plasma RNA sequenced. These two sequences,
which could be considered to be from replicating viruses, are
shown in comparison with the sequence from the 2005 proviral
sample in Figure 6. These two replicating viruses from LTNP 1
changed the six positions identified by the statistical analysis in
this fragment (see Table 4 and Figure 6). In two positions the
replicating viruses recovered the amino acid present in subtype
B consensus (I319, N381). In the other positions, the changes
observed E335, G343, V349 and S392 introduced very unusual
amino acids of the subtype B sequences of LANL database
(frequency of 0.066, 0.026, 0.004 and 0.083 respectively). In
addition to these variations, the replicating viruses also included
other changes, giving net electrical charge, volume or structural
alterations, like N357K, Q358P and S360A in the C3 region
close to the CD4 binding site (364DPE367), which could also
affect to the replication capacity of the viruses. In summary, the
modification of the six residues in the C2-V4 region, specific for
the viral cluster, in the replicating viruses from one of the
cluster patients support the deleterious role of these residues in
viral replication.
Discussion
This work provided evidence that within a cohort of HIV-1
Spanish LTNP, a group of LTNP-controllers were infected by
closely related ancestral virus. The viral cluster was supported by
two independent phylogenetic approaches, ML and Bayesian
inference, both assuming no molecular clock. The existence of an
HIV-1 cluster in LTNP controller patients has not been previously
described in similar cohorts [19,20,41]. We showed that the lack of
clinical progression of the cluster patients could be related to
infection with low replicative viruses.
The objective of the nucleotide analysis was the phylogenetic
reconstruction more than the time frame establishment in the
phylogeny. Consequently, we did not use any molecular clock
approach in the analysis. In both phylogenetic reconstructions,
although samples were collected in 2004–2005, the position of
the cluster nucleotide sequences in the phylogenetic trees, close
to the ancestral nodes of the tree, highlights the ancestral
characteristics of the viral cluster. Viral dating of the sequences
directly from the phylogenetic reconstruction (Figure 2) showed
that the virus of these patients corresponded to the end of 70’s
(see Table 1 and Figure 2). Epidemiological data supported a
linkage between the cluster patients because of IDU practices in
the same city (Madrid, Spain) and in the same period of time.
The clustering of the sequences could not be the consequence of
the same geographical, temporal origin or risk group, because
the other 11 sequences from IDU patients obtained in Madrid
in 1989 and included in Figure 1, were not contained within in
the cluster (Figure 1 and Figure S1).
Gilbert et al. [42] employing many of the samples included in
our set 2 estimated the timing of MRCA of HIV-1 subtype B in
the U.S. epidemic to 1969 (1966–1972). Viral dating of the cluster
nucleotide sequences, shown in Figure 2, was around 1977–1978
suggesting that its introduction in Spain occurred at the beginning
of the HIV-1 epidemic. This assumption is supported by the
epidemiological data which reported the first AIDS case in Spain
in 1981.
After 27–28 years of infection according to this viral dating and
the timing of the cluster samples (2004–2005), a puzzling
characteristic of the cluster viruses is the extremely low intra-
cluster mean genetic distance (0.8%) (Figure 1). This result
establishes a rate of viral evolution of 0.029% nucleotide
substitutions by year and reflects the extremely limited viral
replication produced in these patients. These minimum distances
are even lower than between HIV-1 isolates obtained close to the
transmission event in transmission cases [43–45]. This lack of viral
evolution is also supported by the position of the cluster sequences
and the low genetic distance (4.8%) to the MRCA. Although
samples in Figure 1 included very old sequences (from 1981), this
low genetic distance was found only in 3 sequences (US_81NJ,
ES04_LTNP_2057906 and US04_ES4) out of the 184 analyzed.
The cluster viruses were unable to evolve and replicate in the
different patients, but they established a productive infection.
Transmission of these viruses presumably occurred because of the
intravenous transmission route and probably at a time near primo-
infection [46,47].
The virological analysis carried out in this study focused, as a
first approach, in env gene because of its role for important
phenotypic characteristics. However, this not preclude that other
viral genes may be associated with the lack of replication. There
are other reports on mutations in accessory genes [16] or nef gene
from the Sidney cohort [24] or in other genomic regions like the
59non coding region [48].
The lack of evolution in the env sequences could reflect the
immune pressure exerted by cytotoxic T-lymphocytes, in other
viral genes like gag, pol, nef genes. However, analysis of the
black ancient nucleotide sequences and green subtype B nucleotide sequences. P values for comparison between 2 groups shown with horizontal
black bars were calculated using a 2-tailed Mann-Whitney test.
doi:10.1371/journal.pone.0077663.g003
Table 3. Biological characterization of recombinant viruses




U/ml UA/ml TCID50/ml TCID50/U
LTNP_1_12 (3,260,48)6102 (4,760,04)6102 (6,262,01)6102 1.95
LTNP_1_10 (5,360,75)6102 (5,861,27)6102 (0,6260,10)6102 0.12
LTNP_3_20 (2,560,43)6102 (4,360,22)6102 (0,5760,21)6102 0.22
LTNP_3_22 (1,760,32)6102 (2,2160,15)6102 (4,761,98)6102 2.73
LTNP_3_3 (2,460,54)6102 (3,1360,20)6102 (2,060,58)6102 0.85
LTNP_RF_21 (0,2760,03)6102 (0,3660,04)6102 (0,3960,16)6102 1.46
I10_28 (1,360,15)6103 (2,260,03)6103 (1,4460,35)6104 10.88
IV10_5 (5,160,55)6102 (7,660,04)6102 (6,7960,01)6103 13.36
RIS06_2 (1,160,13)6103 (1,960,01)6103 (1,1560,15)6104 10.89
SF_162 (3,560,34)6102 (5,460,02)6102 (3,2761,47)6104 94.16
WT (6,160,80)6102 (8,961,07)6102 (1,0460,47)6104 17.13
ap24 HIV Ag was determined by the electrochemiluminescence Immunoassay
ECLIA using Elecsys 2010 immunoassay analyzers (Roche Diagnostics).
Quantitative measure indicated that 10 U/ml corresponded to 50 pg/ml of p24
HIV Ag.
bReverse transcriptase activity was quantified using in-house Syber green I-
based real-time PCR enhanced RT assay (SGPERT). 1 UA/ml corresponds to the
RT-activity obtained from a 1026 virus dilution of a viral stock with 106 TCID50/
ml.
Italic font: recombinant viruses from the cluster patients.
doi:10.1371/journal.pone.0077663.t003
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nucleotide sequences in gag gene revealed only the sporadic
presence of mutations, but not in the HLA anchor residues of the
optimally defined CTL epitopes in the viral quasispecies of
patients LTNP_1 and LTNP_3 (Figure 7).
The short length (849 amino acid) and the low number of
PNLGS (26–28) detected in the envelope sequences (Figure 4)
also confirmed the ancestral characteristics and the lack of
evolution of the cluster virus. Changes in PNLGS combined with
enlargement in the hypervariable loop lengths have been related
with active replication and viral evolution along the epidemic
[49–51]. Importantly, all cluster nucleotide sequences maintained
the histidine at position 12 (H12) in the SP recently identified as a
signature of early infection viruses [50]. Data by other groups also
detect a lack of evolution in the proviral compartment of elite
patients suggesting that ongoing replication, if present, is
occurring at a very low rate so as to prevent reseeding of the
Figure 4. Biological characterization of the recombinant viruses. A) Infectivity of env recombinant viruses in TZM-bl cells. Cells were infected
with 15 units of HIV-1 p24 antigen (75 pg) of virus-supernatants. Luciferase activity was measured 48 hours post-infection and the results were
normalized to the value obtained with the WT virus (89ES061). Results represented the median and SE of two independent assays with thee
replicates. B) Replication kinetics of env recombinant viruses in U87-CD4/CCR5 cells. Cells were infected with 100 units of HIV- 1 p24 antigen (500 pg)
of virus supernatants. Cultures were followed during 14 days, and HIV-1 production was quantified by the RT-activity in the supernatant with in-
house Syber green I based real-time PCR enhanced RT assay (SGPERT). Cluster’s recombinant viruses (red) were compared with recombinant viruses
from chronic progressor patients (green), with a recombinant virus obtained from laboratory strain SF-162 (black), and with the laboratory infectious
clone 89ES061 (black) where the nucleotide sequences were cloned.
doi:10.1371/journal.pone.0077663.g004
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latent reservoir [52,53]. All together, these results indicated that
the cluster viruses showed characteristics of early epidemic
viruses.
The amino acid sequences analysis identified unusual residues
in the Env protein (Table 4 and Figure 5). The mutations detected
in V3-C4 region, the SP and the cytoplasmic domain raised the
possibility that the binding to the receptor and co-receptor and the
Env expression levels may be important for the lack of evolution
and low replicative capacity in the cluster virus [54–60]. In
addition, the I322 change in the V3 region has been associated
with the binding to sulfotyrosine residues within the CCR5 amino-
terminal domain essential for CCR5-mediated fusion and entry
[54]. K4E mutation decreases the positive charges in the SP which
are associated with an increase in the rate of gp120 secretion. A
higher folding rate usually leads to a decrease in the yield of
correctly folded molecules [55,56]. Mutation G226D is located in
the amino acid C-terminal tail of the gp41 into the Kennedy
peptide, and is implicated in cell surface Env expression,
incorporation into viral particles, fusogenicity, and localization in
lipid rafts [57–59]. This mutation also results in the V91M change,
in the second coding exon of Tat protein, which is not present in
any subtype B nucleotide sequence of LANL database. Although
the second tat exon is largely devoid of function in vitro, it could be
important for in vivo virus replication and pathogenesis [60]. The
contribution of the identified residues to the lack of viral evolution
is under investigation by in vitro mutagenesis experiments.
Although, additional residues were detected in the replicating
viruses of the only patient in whom we were able to rescue virus
from RNA or co-culture (LTNP_1), all unusual amino acids in
this region were replaced (Figure 6), either recovering the amino
acid present in subtype B consensus or replaced with another
unusual amino acid. These findings support the role of these
residues in the low replicating phenotype. We did not observe any
gross defect, stop-codons, deletions, insertions, in the env
sequences of the cluster viruses. However, we were not able to
recover the viruses by co-culture. This result is consistent with
other reports, where virus co-culture was difficult in the majority
of HIV-1 controllers [19,41,61]. Furthermore, recombinant
viruses obtained with these envelopes showed a very low
replicative capacity (Figure 4). Only two clones, after 14 days
of culture in U87-CD4/CCR5, reached detectable, although low,
levels of replication. The replication levels were 2–100 times
lower than those of reference and control viruses (Figure 4).
Moreover, the lack of viral replication in the cluster viruses could
not be associated with the dominant presence of escape mutations
in CTL epitopes in gag gene associated with a fitness cost [62]
(Figure 7). Infection of the cluster patients with low fitness viruses
has been associated with control of viral replication and disease
control in LTNPs [13,14,21–23].
Several factors could be implicated in the lack of viral evolution
in these patients: host genetic factors, immunological responses,
and/or viral factors compromising biological fitness. In the six
Figure 5. Comparison of the env gene amino acid sequences derived from cluster viruses with subtype B consensus sequence. 35
common mutated positions detected in at least 5 of the cluster viruses are shown in color amino acids. Boxes marked the unusual amino acid whose
presence in the cluster is statistically significant when compared with the reference amino acid sequence sets used in the study (see Table 3).
doi:10.1371/journal.pone.0077663.g005
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cluster patients, we detected an accumulation of host genetic
factors associated with control of viral replication (Table 2) [2]. In
addition, five of the six cluster patients had at least the HLA-B57
or B27 allele and the variant HLA-C35 (rs9264942) in homo or
heterozygosis [7]. The accumulation of these protective alleles in
all cluster patients is not likely to be casual. In addition, the
finding that related viruses with low replication capacity were
present in the cluster patients supported the role of the virus in
the lack of clinical progression. We think that the extreme
phenotype displayed by these patients (no clinical and virological
evolution after 15–20 years of infection) is the result of a
combination of host and virological factors as shown in previous
studies [17,63].
In conclusion, we identified in this report a cluster of LNTP
controller patients infected by closely-related viruses with deleter-
ious characteristics which, because of the restrictive host factors
present in all patients, could not extensively replicate for the
exploration of the sequence space for the replication capacity
improvement. The same clinical outcome in these cluster patients,
with distinct host genotypes, but infected with low replicating
viruses, point to the important role of the virus in the non-
progressor controller clinical phenotype.











N6 of Subtype B
sequences with
polymorphism P value
(N = 6) (N = 50) (N = 110) (N = 452)
GP160 K4E 5 0 3,08E-08 1 2,36E-09 1 5,50E-13
M23L 6 28 0,071 8 1,01E-06 32 2,17E-07
M25I 6 4 6,47E-06 1 2,36E-09 5 3,63E-11
L133W 6 10 2,47E-04 2 9,44E-09 25 5,78E-08
M134R 6 14 1,19E-03 27 3,73E-04 46 1,60E-06
T186S 6 ND ND ND ND 60 7,13E-06
E208D 5 16 0,023 2 7,74E-07 10 1,05E-07
A216T 6 15 1,67E-03 32 9,30E-04 92 8,27E-05
N226K 6 18 4,15E-03 31 7,83E-04 83 4,56E-05
E272D 6 14 1,19E-03 29 5,47E-04 62 8,59E-06
N286K 6 18 4,15E-03 31 7,83E-04 95 9,95E-05
V289I 6 24 0,025 9 1,69E-06 38 5,54E-07
I319T 6 3 2,59E-06 2 9,44E-09 20 1,81E-08
I329L 6 18 4,15E-03 50 0,010 164 2,41E-03
N335D 6 7 5,29E-05 6 3,11E-07 21 2,32E-08
K343R 5 4 1,85E-04 5 9,07E-06 25 4,86E-06
F349L 6 10 2,47E-04 2 9,44E-09 8 2,36E-10
M368T 6 16 2,30E-03 30 6,56E-04 73 2,018-05
N381D 6 5 1,42E-05 11 4,17E-06 55 4,36E-06
T382S 6 29 0,073 61 0,038 138 8,75E-04
G392V 6 5 1,42E-05 10 2,70E-06 32 2,17E-07
GP41 M7V 6 26 0,032 27 3,73E-04 98 1,19E-04
Q32L 6 31 0,085 55 0,028 151 1,48E-03
A96T 6 24 0,025 53 0,027 137 8,39E-04
E110K 6 12 5,72E-04 31 7,83E-04 54 3,93E-06
D113N 6 17 3,11E-03 44 5,36E-03 160 2,08E-03
D125N 6 17 3,11E-03 35 1,52E-03 80 3,69E-05
N166K 6 29 0,073 24 2,00E-04 106 1,88E-04
G226D 5 6 6,55E-04 2 7,74E-07 3 1,99E-09
D239G 6 18 4,15E-03 4 7,08E-08 13 2,13E-09
I245F 5 27 0,223 29 8,14E-03 56 1,91E-04
D247V 6 30 0,078 52 0,027 213 0,011
V322L 6 40 0,352 46 6,86E-03 165 2,50E-03
C326Y 6 18 4,15E-03 34 1,29E-03 81 3,97E-05
R334T 6 30 0,078 44 5,36E-03 156 1,80E-03
AA positions characteristics of the viral cluster that show a statistical significance at the 99.9% level within each sequence set are shown in italic.
AA positions characteristic of the viral cluster with a statistical significance at the 99.9% level simultaneously in the three sequence sets are shown in bold and italic.
doi:10.1371/journal.pone.0077663.t004
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Figure 6. C2-V5 nucleotide sequences from patient LTNP_1. LTNP_1 samples were obtained from PBMC DNA (2005 sample), cell-free
supernatant of PBMC co-culture from a 2004 sample and plasma RNA corresponding to a 2010 sample. Shaded boxes indicated amino acid mutations
characteristics of the cluster viruses in this C2-V5 region. V3, V4 and V5 regions are indicated by boxes.
doi:10.1371/journal.pone.0077663.g006
Figure 7. Analysis of HLA-B*57/58 and HLA-B*27 epitopes in gag nucleotide sequence from the cluster viruses. Amino acid sequences
alignment in gag gene from the cluster viruses. The most important HLA-B*57/58 (blue) and HLA-B*27 (green) epitopes described in the literature are
marked. Bars indicated the start position of the different proteins in HIV-1 gag gene. X specified mixed position in the nucleotide sequences.
doi:10.1371/journal.pone.0077663.g007
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Supporting Information
Figure S1 Phylogenetic analysis in the C2-V5 env region
of proviral nucleotide sequences in Spanish LTNPs and
chronic patients. The Maximum Likelihood tree was calculated
with PAUP* version 4.0b incorporating the optimal evolutionary
model and its parameters (Modeltest v.3.7) in a heuristic search.
Box indicated nucleotide sequences of the virus cluster obtained
from patients LTNP_1 (black ), LTNP_3 (red ), LTNP_5
(gray ), LTNP_RF_15 (light blue ), LTNP_RF_21 (dark blue )
and AS7 (green ). Numbers before nucleotide sequence name
indicated sampling year. Black letters designated proviral nucleo-
tide sequences obtained from LTNP patients. Red letters specified
proviral nucleotide sequences obtained from chronic patients.
(TIF)
Figure S2 Clinical and virologic follow-up from cluster
patients. Longitudinal assessment of plasma viral loads (red &),
CD4+ T cell (blue m) and CD8+ T cell (green .) counts during the
HIV-1 infection. Empty squares represent plasma viral load
determined with a detection limit of 500 copies/ml.
(TIF)
Table S1 Epidemiological, clinical and viral character-
istics of the set 1 (Spanish patients).
(DOC)
Table S2 Identification of the Set 2 patients.
(DOC)
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